Mean IL-6 Levels Research Articles

Clinicopathological Factors and Interleukin-6 Levels Associated With Low Relative Dose Intensity in Women With Breast Cancer Receiving First-Line Chemotherapy.

Chemotherapy has a substantial role in decreasing the risk of recurrence and mortality in breast cancer (BC) in a dose-dependent manner where a low relative dose intensity (RDI) is associated with unfavorable outcomes. Several baseline clinicopathological factors, including pro-inflammatory biomarkers, were found to be significant determinants of low RDI. This study aimed to explore the occurrence of low RDI and its influencing factors in women with BC. This cross-sectional study recruited 172 women with stage I-IV BC who received first-line chemotherapy. We collected patients' clinical, pathological, and treatment data and analyzed the pre-chemotherapy C-reactive protein (CRP) and interleukin (IL)-6 levels using a quantitative enzyme-linked immunosorbent assay (ELISA). We calculated the RDI based on the actual and planned delivered chemotherapy dose (mg/m2) and duration (weeks). RDI less than 85% was defined as "low". Multivariate analysis with logistic regression was conducted to determine the association between pre-chemotherapy parameters and RDI < 85%. The mean CRP level was 10.82 ± 19.17 mg/L (0.00 - 151.73 mg/L) and the mean IL-6 level was 1.12 ± 3.41 pg/mL (0.00 - 27.67 pg/mL). The average RDI for all patients was 93±8.19%. An RDI < 85% occurred in 23 patients (13.4%). The presence of diabetes mellitus (odds ratio (OR): 4.78, 95% confidence interval (CI): 1.03 - 22.27, P = 0.046), triple-negative tumors (OR: 6.45, 95% CI: 1.39 - 29.83, P = 0.017), and IL-6 levels > 0.5 pg/mL (OR: 3.45, 95% CI: 1.01 - 11.79, P = 0.049) was associated with an increased low RDI risk. The proportion of BC patients receiving a low chemotherapy RDI in our study was comparable to published literature and drove close monitoring of patients at risk to provide adequate management.

Evaluation of Interleukin-6 Levels in Patients with Type 2 Diabetes Mellitus

Background: It has been suggested that inflammatory processes play an important role in the pathogenesis of type 2 diabetes. Individuals who develop type 2 diabetes show signs of low-grade inflammation years before disease onset. This low-grade inflammation has been assumed to be implicated in the pathogenetic mechanisms that cause type 2 Diabetes Mellitus. Inflammatory mediators such as the IL-6 family of cytokines have been proposed to be involved in the events that lead to type 2 diabetes. IL-6 has immunoregulatory actions been proposed to affect glucose homeostasis and metabolism directly and indirectly by action on skeletal muscle cells, adipocytes, hepatocytes, pancreatic b-cells and neuroendocrine cells. Many studies have suggested the role of IL-6 in the pathogenesis of type 2 diabetes mellitus. However, no references have been observed in Bangladesh regarding IL-6 and its association with type 2 diabetes mellitus. It thus may highlight the importance of low-grade inflammation in the pathophysiology of type 2 diabetes mellitus. The purpose of this study was to evaluate type 2 diabetes patients' levels of interleukin-6. Materials and methods: A hospital-based cross-sectional observational study was carried out in the Department of Biochemistry Chittagong Medical College, Department of Endocrinology of Chittagong Medical College Hospital and Chattogram Diabetic Hospital. One hundred (100) type 2 diabetes mellitus patient was included in the study by nonprobability consecutive sampling. Important variables in this study were serum IL-6, BMI, waist circumference and duration of Diabetes Mellitus. Results: The mean serum IL-6 level was 10.08±0.39 pg/ml in patients with type 2 Diabetes Mellitus. Serum IL-6 was positively correlated (r 0.33, p &lt;0.01) with waist circumference and duration of diabetes mellitus (r 0.26, p &lt;0.05). The mean IL-6 was significantly different between BMI groups (F (2,97) =5.39, p=0.006) and was higher in the obese group (10.52±4.00) compared to the overweight and normal BMI (6.78±1.95) and overweight (8.08±3.15) group. Conclusion: It can be concluded that type 2 diabetes mellitus patients had increased serum levels of IL-6. It can give an insight into the possible role of sub clinical inflammation among patients with type 2 Diabetes Mellitus. IAHS Medical Journal Volume 6(2) December 2023; 53-57

The Burden of Chronic Obstructive Pulmonary Disease COPD in Stable Patients and its Association with Inflammatory Biomarkers and Body Mass Index

Background: Chronic obstructive pulmonary disease (COPD) is a progressive airflow limitation that is preventable but not curable. It is associated with persistent symptoms that cause a considerable burden on individual productivity at work, and daily activities, and reduced quality of life, also burdening the healthcare system and society. Objectives: The study aims to measure the burden of COPD on patients in terms of daily activities and work productivity. It also seeks to investigate some inflammatory biomarkers' levels and their correlation with selected outcomes. Patients and Methods: A cross-sectional study on 120 stable COPD patients who were diagnosed and treated according to the GOLD guidelines at Kirkuk General Hospital's chest and Internal Medicine consultation clinics, and in private internist clinics in Kirkuk City, Iraq between January and April 2023. The Work Productivity and Activity Impairment Questionnaire (WPAI-COPD) measured the Burden of COPD. The symptom burden was assessed by the COPD assessment test (CAT). The level of IL-6 monoclonal antibodies was measured via a Roche Cobas 6000 analyzer and TNF-α using the ELISA sandwich technique. All these devices and machines were authorized by the Ministry of Health, Iraq. Results: The mean age was (54.1 ± 8.12) years, 62.5% being males and 37.5% being females; 41.7% were public sector employees, and 39.2% were self-employed. Due to COPD, the overall work loss was (45.9±18.91) days, the mean percentage of absenteeism was (10.9% ± 12.31%), activity impairment was (47.5% ±17.79%) among all patients, presenteeism was (40.8 ± 15.05%,) and COPD-related retirees were 14.2% of the study group. The mean CAT score (19.3±5.63) was high and the most troubling symptom among patients was chest tightness. WPAI-COPD scores were higher in older age and longer disease duration. The levels of biomarkers were above the reference ranges, the mean IL-6 level was (69.4 ± 35.29) pg/ml, and the mean TNF-α was (72.3 ± 22.45) pg/ ml. Conclusions: COPD patients exhibit a disease burden in terms of productivity loss at work and activity impairment that increases with aging and disease duration. COPD patients with low BMI are more prone to a decline in lung functions and to worse symptoms.

Influence of Diclofenac Potassium versus Prednisolone on Postendodontic Pain and Pulpal Interleukin-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Placebo-controlled Trial

AimThis prospective, randomized, double-blind clinical trial investigated the impact of diclofenac potassium, prednisolone, and placebo as oral premedication on postendodontic pain and pulpal interleukin (IL)-8 expression in patients with irreversible pulpitis. MethodsThirty-six patients undergoing conventional endodontic treatment were assigned into one of 3 groups (n = 12). Pulpal blood samples were taken after access cavity preparation and stored until they were analyzed using enzyme-linked immunosorbent asssay for quantification of IL-8. Postendodontic pain was scored using the visual analogue scale. Outcome data were statistically analyzed using one-way analysis of variance, Kruskal-Wallis, Friedman's, Dunn's, Chi-square, and Fisher's exact tests and Spearman's correlation coefficient. The significance level (α) was set at 0.05. ResultsApart from preoperative pain scores, all groups had similar baseline characteristics (P > .05). Immediate postendodontic pain scores had a significant difference between all groups (P < .05) where placebo group showed the highest score. There was no significant difference between all groups at 6 and 12 hours postoperatively (P > .05). Furthermore, there was no significant difference in the incidence of postendodontic pain and in mean IL-8 levels between the 3 groups (P > .05). ConclusionsThe only impact the premedications had was on the immediate postendodontic pain intensity, and they had no influence on the later time points, incidence of postendodontic pain or pulpal IL-8 levels.

Inflammatory Patterns in the Prostate Gland and Serum Cytokine Activities in Primary Adenocarcinoma of the Prostate in Port Harcourt, Nigeria

Introduction: Chronic inflammation and pro-inflammatory cytokines such as (1L-6 and TNF-α) have been implicated in prostate carcinogenesis and metastasis. This study aims to evaluate serum concentrations of IL-6 and TNF-α, and to determine their association with clinicopathological patterns of prostate cancer in affected patients. Materials and Methods: Ninety (90) patients with histologically diagnosed prostate cancer (PCa), treated at the Urology Division of the University of Port Harcourt Teaching Hospital (UPTH), Nigeria were involved in this study. The enzyme-linked immunosorbent assay (ELISA) technique was used to assay cytokines (IL-6 and TNF-α), and serum PSA. Gleason Scores were categorized as well differentiated (GS of ≤ 6), moderately differentiated (GS = 7), and poorly differentiated (GS 8-10). Results were analyzed with IBM SPSS version 20.0. Pearson’s correlation test was used to determine the correlation between the cytokines (IL-6 and TNF-α) and Gleason Scores. Results: The modal age group with PCa was 60-69 years. The mean age of patients was 68.788.26 years, and the mean serum PSA 93.2478pg/ml. Serum levels of IL-6 and TNF-α were 8.0pg/ml, 11.2pg/ml and (27.0±26.4pg/ml) respectively. Forty-six subjects had poorly differentiated PCa (GS 8-10); 17 moderately differentiated (GS 7); and 27 well differentiated (GS ≤ 6). Mean serum levels of IL-6, TNF-α and PSA (113.1ng/ml) were raised and found highest in those with poorly differentiated PCa. Conclusion: The observed correlation was positive but weak. The patients might have commenced undeclared anti-inflammatory drugs that depressed inflammation. However, a larger sample size would probably confirm the prognostic value of IL-6 and TNF-α in PCa subjects.

The Association of Cytokines IL-2, IL-6, TNF-α, IFN-γ, and IL-10 With the Disease Severity of COVID-19: A Study From Bangladesh.

Introduction Clinically, the early prediction of the severity of COVID-19 is often challenging, as a dramatic change in severity can occur without warning. The severity of COVID-19 disease is associated with an increased level of inflammatory mediators, including cytokines. This study aimed to evaluate the association of the levels of cytokines interleukin (IL)-2, IL-6, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and IL-10 with the severity of COVID-19 in Bangladesh. Materials and methods This cross-sectional study included a total of 60 confirmed cases of COVID-19, comprising 30 severe cases (Group A) and 30 non-severe cases (Group B), and 10 healthy individuals (Group C) attending Bangabandhu Sheikh Mujib Medical University (BSMMU) from March 2021 to February 2022. The cytokine assay was performed using the human Th1/Th2/Th17 cytokine kit BD cytometric bead array (CBA) on the BD Accuri C6 Plus flow cytometer. Statistical analysis was conducted using IBM SPSS Statistics for Windows, Version 23 (Released 2015; IBM Corp., Armonk, New York). Results The mean ages of the patients in Groups A, B, and C were 60.73±5.97, 57.13±7.68, and 48.10±9.13 years, respectively, with a male predominance in all groups. The mean IL-2, IL-6, IL-10, and TNF-α levels had a positive correlation with the increased age group and male gender, although it was not statistically significant. The mean IL-6 and IFN-γ levels were significantly higher among severe cases (216.95±147.78 and 0.98±0.95 pg/mL, respectively) compared to non-severe cases (94.29±128.79 and 0.41±0.61 pg/mL, respectively) and healthy individuals (1.08±1.97 and 0.15±0.28 pg/mL, respectively). Furthermore, the anti-inflammatory cytokine IL-10 was also significantly higher among severe cases (17.92±21.87 pg/mL) compared to non-severe cases (5.38±6.73 pg/mL) and healthy individuals (1.62±1.65 pg/mL). Conclusion IL-6, IFN-γ, and IL-10 have a significant association with the severity of COVID-19 disease. Clinicians treating patients with COVID-19 can consider the level of these cytokines as biomarkers of severity.

Empagliflozin reduces the adverse effects of diabetes mellitus on testicular tissue in type 2 diabetic Rats: A stereological and biochemical study

Empagliflozin as an antioxidant decreases blood glucose and insulin resistance in type 2 diabetes mellitus. Base on the empagliflozin antioxidant properties we decided to investigate the its effects on the testis histological changes through stereological techniques and biochemical evaluations in T2 diabetes mellitus rats. Rats were divided into: control, diabetes mellitus (DM, streptozotocin + nicotinamide) and diabetes mellitus + empagliflozin (DM + EMPA, 10 mg/kg/day) groups. 56 days after inducing diabetes mellitus testis histological changes and serum biochemical factors along with the level of Bax, Bcl2 and Nrf2 genes expression in the testicular tissue were assessed. A significant decrease in the mean total volume of testis and its components, the level of Bcl2 and Nrf2 gene expression (p < 0.001) along with a significant increase in the level of IL-6, TNF-α, MDA, Bax gene expression were observed in the DM group compared to the control group (p < 0.001). In the DM + EMPA group, the mean total volume of testis and its components, the level of Bcl2 gene expression (p< 0.01) and Nrf2 (p < 0.001) significantly increased whereas the mean level of IL-6 (p < 0.01), TNF-α (p < 0.001), MDA (p < 0.001), Bax (p < 0.001) gene expression significantly decreased compared to the DM group. Our results showed that empagliflozin, by improving the antioxidant defense system, can reduce testicular inflammation and apoptosis and partly prevent the adverse effects of diabetes mellitus on testicular tissue.

NF-α, IL6, IL1-α, IL-10 and TGF-β1 Gene Expression in Iranian Acute Myeloid Leukemia Patients

Acute myeloid leukemia is a heterogeneous clonal disorder of blood-producing cells that are among the most common malignant disorders in adults. The purpose of this study was to examine the gene expression of TNF-α, IL6, IL1-α, IL-10, and TGF-β1 at diagnosis in acute myeloid leukemia. The current study included 50 patients with acute myeloid leukemia and 50 control subjects. ELISA was used to determine the serum concentrations of TNF-α, IL6, IL1-α, IL-10, and TGF-β1. After cDNA synthesis and RNA extraction, the expression of TNF-α, IL6, IL1-α, IL-10, and TGF-β1 genes was determined using real-time PCR (ΔΔCT computational). Statistical analysis was conducted with Statistical Package for the Social Sciences 19, and P&lt;0.05 was deemed statistically significant. The mean serum levels of TNF-α, IL6, IL1-α, IL-10, and TGF-β1 were lower in patients with acute myeloid leukemia than in the control group. In addition, cytokine mRNA expression in peripheral blood mononuclear cells was significantly lower in AML patients compared to the control group (p&lt;0.0001). Changes in TNF-α, IL6, IL1-α, IL-10, and TGF-β1 were associated with acute myeloid leukemia, according to the findings. The current study supports the use of cytokines as diagnostic biomarkers for acute myeloid leukemia.

Relationship between Levels of Interleukin-6 and Tumour Necrosis Factor Alpha and Khorana Scores of Newly Diagnosed Ambulatory Cancer Patients

Abstract Background: In cancer microenvironment, there is increased production of inflammatory cytokines, including tumour necrosis factor (TNF)-α, interleukin (IL)-1a, and IL-6. These cytokines are capable of causing thrombus formation through the activation of tissue factors. Then, the Khorana risk score can be Utilised to stratify the risk of venous thromboembolism in cancer patients. Aim: The objective of this study was to determine the relationship between levels of IL 6, TNF-α, and Khorana scores of chemotherapy-naïve ambulatory cancer patients (CNACPs). Materials and Methods: This was a cross-sectional study. The case group (n = 100) consisted of newly diagnosed CNACP recruited from adult oncology clinics of University of Nigeria Teaching Hospital, Ituku-Ozalla Enugu, Nigeria, whereas the control group (n = 100) consisted of healthy individuals. The participants’ blood samples were assayed by enzyme-linked immunosorbent assay (ELISA) technique for IL-6 and TNF-α. Demographic variables were analysed using descriptive statistics in the form of frequencies and percentages and P &lt; 0.05 was considered statistically significant. Results: There were significant differences between the mean levels of IL-6 (P = 0.036) and TNF-α (P = 0.001) in three Khorana score groups of the case group. Further, comparisons of mean IL-6 levels between three Khorana score groups showed that differences were between high-risk versus low-risk groups (P = 0.026) and between intermediate-risk versus low-risk groups (P = 0.014). Comparison of mean TNF-α levels in three Khorana score groups of CNACP showed that differences were between high-risk versus low-risk groups (P = 0.026) and between intermediate-risk versus low-risk groups (P = 0.014). Furthermore, there was a significant positive correlation between the Khorana scores and IL-6 (r = 0.28, P = 0.031) and TNF-α (r = 0.254, P = 0.011). The mean serum levels of IL-6 and TNF-α were significantly higher in CNACP than in healthy control (8.98 [8–12] pg/ml vs. 8.43 [2–10] pg/ml, P &lt; 0.001) and (P &lt; 0.001 and &lt; 0.01), respectively. Conclusion: Inflammatory biomarkers are elevated in ambulatory CNACP and their values are significantly related with Khorana scores. There is a need for more studies on the possible benefit of prophylactic anticoagulation for newly diagnosed CNACP.

Role of Serum Interleukin-6, Interleukin-1β and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease.

Inflammatory bowel diseases (IBD) are characterised by multifactorial and chronic inflammation. Much attention has been paid to immune dysfunction in inflammatory bowel diseases. The aim of this study was to assess the usefulness of serum IL-6, IL-1β and IL-10 in determining the activity and nutritional status in IBD patients. The case-control study was carried out on 82 patients with IBD; the control group consisted of 25 clinically healthy subjects. The serum concentrations of IL-6, IL-1 β and IL-10 were determined by the quantitative sandwich enzyme-linked immunosorbent assay. There were no significant differences in IL-6 and IL-1β levels in UC and CD patients according to disease activity as assessed by the Montreal classification, Partial Mayo Score and CDAI. Significantly higher IL-6 levels were found in patients with low body fat in comparison to patients with normal body fat. Furthermore, significantly higher mean IL-6 levels were observed in patients with excess body fat in comparison to patients with normal body fat, and also in comparison to patients with deficient body fat. IL-6 and IL-1β may provide extra information regarding the nutritional status of IBD patients. IL-10 can be considered a non-invasive biomarker of IBD activity.

Effect of Steeping Green Tea (Camellia Sinensis L.) Against IL6 and IL 10 Levels in Rats Exposed to Cigarette Smoke

The prevalence of smokers in Indonesia is more than 25% of the total population. Cigarette smoke contains numerous free radicals that trigger the formation and increase of Reactive Oxygen Species (ROS) within the body, leading to inflammation and cytokine production. Green tea contains catechins known for their potent antioxidant properties. This study aims to assess the levels of Interleukin 6 and Interleukin 10 in rats exposed to cigarette smoke. The research method used was the post-test only control group design, involving 24 male Wistar rats divided into 4 groups: Normal group (N), Control - (Cigarette Smoke), Control + (Cigarette Smoke + 1.44 mg/day Vitamin E), P. (Cigarette Smoke + 3.6 ml Green Tea Infusion). Interleukin 6 and Interleukin 10 levels were measured after 14 days of treatment. Data were analyzed using One Way Anova. The mean IL-6 level in the Control (-) group was the highest (141.75±6.24 pg/ml), while the Sham group had the lowest (73.58 ± 4.57 pg/ml) IL-6 level. One Way Anova results showed a p-value of &lt;0.001 for both IL-6 and IL-10 levels, indicating a significant difference among the four groups. Post Hoc LSD test results indicated that the IL-6 levels in the K(+) group were relatively similar to the IL-6 levels in the P group (p=0.172). Post Hoc LSD test results for IL-10 levels between the two groups were all significant, with a p-value of &lt;0.001. The administration of green tea infusion was shown to affect the Interleukin 6 levels, while green tea infusion did not have a significant impact on Interleukin 10 levels in white rats exposed to cigarette smoke.

Phytotherapy (BNO 1045) of Acute Lower Uncomplicated Urinary Tract Infection in Women Normalizes Local Host Responses

Introduction: Acute lower uncomplicated urinary tract infection (uUTI) affects a large proportion of women. Increased antimicrobial resistance has created an urgent need for novel therapeutics and the phytotherapeutic drug BNO 1045 (Canephron^® N) has previously been shown to be noninferior to standard antimicrobial stewardship. This sub-analysis from a randomized, double-blind, controlled phase III noninferiority clinical trial using BNO 1045 versus fosfomycin to treat uUTI aimed to determine how urine cytokine levels are altered by the two different treatments. Methods: Urine samples from a predefined subset of women diagnosed with uUTI (18–70 years) and treated with BNO 1045 (n = 58) or fosfomycin (n = 69) were analyzed for urine levels of IL-6 and IL-8, using analyte-to-creatinine ratios. Results: BNO 1045 treatment showed similar effects to fosfomycin treatment in reducing both urine IL-6 and IL-8 levels. Mean IL-6 and IL-8 levels were markedly reduced in all patients regardless of treatment. BNO 1045 treatment decreased urine IL-8 significantly (p = 0.0142) and showed a trend toward reduction of urine IL-6 (p = 0.0551). Fosfomycin treatment reduced both IL-6 and IL-8 levels significantly (p = 0.0038, <0.0001 respectively). Conclusion: BNO 1045 is, in addition to reducing symptoms, comparable to fosfomycin treatment in reducing the local inflammatory response associated with uUTI.

Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection

Cytokines have a crucial part in the pathogenesis, persistence of infection, and prognosis of hepatitis B virus (HBV) infection as HBV does not cause direct liver destruction; rather, disease-related complications and prognosis are more associated with immune system action, specifically cytokines such as TNF-α, IFN-γ, IL-6, IL-10, and other cytokines. This study sought to link TNF-, IFN-, IL-6, and IL-10 to various clinical manifestations of HBV infection. Ninety sera were taken from HBV-infected patients, 30 (33.3%) of whom had liver cirrhosis, 30 (33.3%) were HBV carriers, 19 (21.2%) were acute HBV patients, and 11 (12.2%) were recently HBV infected. ELISA was used to determine the serum levels of TNF-α, IFN-γ, IL-6, and IL-10. HBV-infected patients with liver cirrhosis had considerably higher mean serum levels of IFN-γ (P=0.005) and IL-10 (P=0.003), but TNF-α and IL-6 were significantly higher in recent HBV-infected patients (P values 0.034 and 0.004, respectively). There were substantial changes in mean serum levels of TNF-α, IFN-γ, IL-6, and IL-10 at different phases of HBV infection, implying a role for cytokines in HBV etiology, chronicity, and consequences.

Association of serum vitamin D status with serum pro-inflammatory cytokine levels and clinical severity of fibromyalgia patients

The role of vitamin D deficiency in fibromyalgia (FM) pathogenesis is not clearly understood. In this study, we evaluated the association of serum vitamin D status of FM patients with laboratory indices of inflammation, as well as clinical indices of FM. Ninety-two female FM patients with a mean age of 42.4±7.4 years were included in this cross-sectional study. Serum vitamin D, serum IL-6, and serum IL-8 levels were evaluated using an enzyme-linked immunosorbent assay. Serum vitamin D levels were categorized as deficient (<20ng/ml), insufficient (20-30ng/ml), and sufficient (30-100ng/ml). The clinical severity of the disease was assessed by the fibromyalgia impact questionnaire (FIQ) and widespread pain index (WPI). The mean serum IL-6 level was significantly higher in vitamin D-deficient patients in comparison with vitamin D-sufficient patients (P=0.039). The mean serum IL-8 level was also significantly higher in vitamin D-deficient patients in comparison with vitamin D-sufficient patients (P<0.001). A significant positive correlation was found between the serum IL-8 level and FIQ scores (r=0.389, p=0.001) and the WPI of the patients (0.401, p<0.001). Serum IL-6 level was significantly correlated with the WPI of the patients (r=0.295, p=0.004), but not with FIQ scores (r=0.134, p=0.066). Serum vitamin D status was not associated with either FIQ scores or WPI. In FM patients, serum vitamin D deficiency is associated with higher levels of serum pro-inflammatory cytokines, and higher levels of serum pro-inflammatory cytokines are associated with greater FM impact.

The effect of non-surgical periodontal therapy on salivary IL-6 levels in patients with moderate to severe generalized chronic periodontitis.

Generegulation of IL-6 is characterized by the presence of inflammatory cytokines, bacterial products, viral infection, andactivation of the diacylglycerol-, cyclic AMP-, or Ca + + -activated signal transduction pathways. Scaling and root planning (SRP), a non-surgical periodontal therapy, was studied in connection toseveral clinical parameters for its effect on salivary IL-6 levels in patients with generalized chronic periodontitis. For this study, a total of 60 GCP patients were included. Plaque index (PI), gingival index (GI), pocket probing depth (PPD), bleeding on probing percentage (BOP%), and clinical attachment loss were among the clinical indicators covered (CAL). Following SRP, mean IL-6 levels in patients with GCP were significantly higher in the pre-treatment group (2.93 5.17 pg/ml; p 0.05) than in the posttreatmentgroup (5.78 8.26 pg/ml; baseline). Pre- and post-treatment IL-6 levels for PI (pre), BOP percent (pre/post), GI (post), and PPD were found to be positively correlated (post). In patients with GCP, the study showed a statistically significant correlation between periodontal metrics and salivary IL-6. Changes in periodontal indices and IL-6 levels that are statistically significant over time indicate that non-surgicaltreatment is effective, and IL-6 can be regarded as a potent disease activity marker.

Assessment of salivary and gingival crevicular fluids IL6, IL-8, IL-12, and IL-17 levels in healthy subjects and patients with periodontal disease.

Biomarkers present in the oral fluid (saliva and GCF) have been studied thoroughly in order to be used as adjuncts to the diagnosis of periodontal disease. In periodontal diseases, inflammatory mediators, including IL6, IL-8, IL-12, and IL-17, may promote the degeneration of periodontal tissues. The aim of the present study was to quantify IL6, IL-8, IL-12, and IL-17 levels in the saliva and GCF for patients with generalized periodontitis and compare it with healthy subjects. Furthermore, identifying the most reliable biofluids (saliva and GCF) that can be utilized for biomarkers detection in periodontitis patients. In this study, GCF and saliva samples were collected from 40 patients with generalized periodontitis and 20 healthy subjects. Enzyme-linked immune absorbent assay (ELISA) was used in the measurement of interleukin levels. The mean levels of IL6, IL-8, IL-12, and IL-17 either in saliva or GCF were higher in periodontitis patients than in healthy subjects. These results suggest that the levels of IL6, IL-8, IL-12, and IL-17 in GCF or saliva may be relevant in the pathophysiology of periodontitis, and the measurement of these cytokines may be beneficial in the identification of patients with periodontitis. Furthermore, some biomarkers for periodontal disease are detected better in saliva, while others are best detected in GCF.

Expression and clinical significance of IL-6 in patients with allergic rhinitis

Background: Allergic rhinitis is a chronic inflammatory disease with a high incidence affecting the quality of life of patients. The objective of the study was to explore the expression and clinical significance of IL-6 in patients with allergic rhinitis. Methods: This cross-sectional analytical study was conducted in the department of ENT, H&amp;NS, Government Medical College, Srinagar. A total of 180 patients were included in the study, out of them 90 patients with allergic rhinitis were cases and 90 patients comprised the control group who did not have allergic rhinitis. The recorded data was compiled and entered in a spreadsheet (Microsoft Excel) and then exported to data editor of SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). Results: A total of 184 patients participated in the study. The mean age in case group was 35.7±15.46 years compared to control group which was 37.1±12.89 years. There was male dominance in both the groups. Comparison of IL-6 levels as per severity of allergic rhinitis was assessed in this study and it was found that in patients with severe allergic rhinitis the mean IL-6 levels were 65.2±5.32; in moderate, patients had IL-6 levels of 52.8±5.84 and in mild patients had IL-6 levels of 46.7±6.81. Conclusions: Clinical testing of IL-6 is likely to improve the diagnostic rate of early allergic rhinitis and help in halting the progression of disease and improve the patients prognosis and reduce symptoms and morbidity. Higher the levels of IL_6 more severe will be the allergic rhinitis.

Longitudinal study of inflammation and relapse in schizophrenia

IntroductionThe clinical course of schizophrenia is often characterized by recurrent relapses. Blood inflammatory markers are altered in acute psychosis, and may be state markers for illness relapse in schizophrenia. Few studies have investigated longitudinal, intra-individual changes in inflammatory markers as a predictor of relapse. In the present study, we explored this association in a relapse prevention trial in patients with schizophrenia. MethodsWe analyzed blood inflammatory markers in 200 subjects, with a mean 11 samples per subject, during the 30 month Preventing Relapse in schizophrenia: Oral Antipsychotics Compared to Injectable: eValuating Efficacy (PROACTIVE) trial. Associations between longitudinal changes in inflammatory markers and relapse were analyzed using a within-subjects design. Results70 (35 %) of subjects relapsed during the study period. There were no significant differences in mean inflammatory marker levels based on relapse status (yes/no). Baseline levels of inflammatory markers did not predict incident relapse. Among subjects who relapsed, there was a significant decrease in mean blood IL-6 (n = 38, p = 0.019) and IFN-γ (n = 44, p = 0.012) levels from the visit before the relapse to the visit after relapse. ConclusionAlthough there was some evidence for inflammation as a potential state marker for acute psychosis, we did not find significant evidence for its utility as a relapse-predictive marker.

Interleukin-6 and interleukin-8 levels in children with aplastic anemia and its correlation with disease severity and response to immunosuppressive therapy.

Aplastic anemia (AA) is an uncommon condition characterized by pancytopenia and hypocellular bone marrow. Interleukin (IL)-6 and IL-8 have been shown to inhibit myelopoiesis and are major mediators of tissue damage. The primary goal of this study was to determine the IL-6 and IL-8 levels in children with AA, as well as their relationship to illness severity and immunosuppressive medication response. The IL-6 and IL-8 levels were tested in 50 children aged 3-18 years who had AA. As controls, 50 healthy age and sex matched individuals were used. A sandwich enzyme-linked immunosorbent assay kit (solid-phase) was used to measure IL-6 and IL-8 levels quantitatively. The concentrations of IL-6 and IL-8 in pg/mL were used to represent the results. Immunosuppressive medication was given to the patients in accordance with the British Committee for Standards in Haematology Guidelines 2009. The patients' average age was 11.3 ± 3.7 years. Patients with AA had significantly higher IL-6 and IL-8 levels than controls (278.88 ± 216.03 vs. 4.51 ± 3.26; P < 0.001) and (120.28 ± 94.98 vs. 1.79 ± 0.78; P < 0.001), respectively. The IL-6 and IL-8 levels were also investigated with respect to AA severity, with statistically significant differences (P < 0.01) between different grading strata. Patients with very severe AA (VSAA) had the highest IL-6 levels (499.52 ± 66.19), followed by severe AA (SAA) (201.28 ± 157.77) and non-SAA (NSAA) (22.62 ± 14.63). For IL-8 levels, a similar trend (P < 0.01) was detected, with values of 209.81 ± 38.85, 92.12 ± 78.0, and 9.29 ± 10.68 for VSAA, SAA, and NSAA, respectively. After 6 months of immunosuppressive treatment (IST), mean levels of IL-6 and IL-8 in responders and nonresponders were again assessed. The mean IL-6 level in the responders' group (46.50 ± 45.41) was significantly lower, when compared to the nonresponders' group (145.76 ± 116.32) (P < 0.001). Similarly, the mean IL-8 level in the responder's group (33.57 ± 27.14) was significantly lower, compared to the nonresponder's group (97.49 ± 69.00) (P < 0.001). Children with AA had higher IL-6 and IL-8 levels than normal age- and sex-matched controls. Increased levels were linked to the severity of the condition, suggesting that IL may have a role in AA. IL levels can be monitored in AA patients during IST, which can assist in predicting response to IST.

INTERLEUKIN-6 AND NKG2D AS PROGNOSTIC FACTORS IN IRAQI FEMALES WITH PITUITARY GAND ADENOMA: A LONGITUDINAL STUDY.

The aim: To assess the role of circulating IL-6 & NKG2D in the prognosis of pituitary adenoma. Materials and methods: Thirty female with new diagnosis of prolactinoma (pituitary gland adenoma) were enrolled in the study. ELISA test was used to evaluate the level of IL6 and NKG2D. ELISA tests were conducted before the initiation of treatment and six months later. Results: There are significant differences in mean levels of IL-6 and NKG2D, and the anatomical type (tumor size) (-418.7 & 418.9, p<0.001) of anatomical tumor (-373.72 & -373.920, p=0.001). There is a significant difference between the two immunological markers (IL-6 & NKG2D) (-0.305; p<0.001). The IL-6 markers significantly decreased in means on follow up (-197.8; p-value≤0.0001) while the reverse occur in NKG2D, which increased in levels post-treatment compared with baseline measurement. The high expression of IL-6 positively correlated with the risk of macroadenoma (>10 microns) and poor resonse to treatment and vice versa (p<0.024). High expression of NKG2D significantly (p<0.005) correlated with good prognosis and increased chance for tumor response to medicine and shrinkage in size compared with low concentration. Conclusions: The higher the level of IL-6, the larger the size of adenoma (macroadenoma) and the poorer the response to treatment. The higher the level of NKG2D indidcate a better prognosis, therefore, IL-6 and NKG2D correlate negatively in prolactinoma patients.